Evaluation of the role of travoprost 0.004% ophthalmic solution in the management of open angle glaucoma and ocular hypertensive patients.
To assess the intraocular pressure lowering effect of travoprost 0.004% in previously treated and untreated open-angle glaucoma and ocular hypertensive patients. This was a 3-month, multi-centre, open-label trial involving 1133 patients, conducted at 61 sites in Eastern Europe. Previously treated open-angle glaucoma or ocular hypertensive patients either had all or part of their existing therapy replaced with travoprost or had travoprost added to existing therapy, depending on the clinical judgment of the investigator. Untreated patients were also started on travoprost. In all patients travoprost was given once daily in the evening. Patients returned for follow-up visits at 1 and 3 months. The primary outcome variable was mean IOP change from baseline. A total of 1,109 patients were available for analysis of efficacy; 731 used travoprost as replacement therapy (665 complete and 66 partial), 176 as adjunctive therapy; and 202 had not previously been treated. Mean IOP decreased by approximately 19-22% in replacement therapy patients; 26-29% in adjunctive therapy patients; and 27-30% in previously untreated patients. Replacement of beta-blocker monotherapy and latanoprost monotherapy by travoprost was accompanied by a 21-24% and 13-17% decrease in mean IOP respectively. The results from this study support the concept that the majority of glaucoma patients, who are responding inadequately to other glaucoma therapies, could benefit from a change to travoprost monotherapy or from the addition of travoprost to their existing therapy.